Phase 3 HPV Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
HPV-Related Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center291 enrolled9 locationsNCT06563479
Recruiting
Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine81 enrolled5 locationsNCT04966481
Recruiting
Phase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Human Papilloma Virus (HPV)WartsCommon Warts+1 more
Verrica Pharmaceuticals Inc.300 enrolled6 locationsNCT07246590
Recruiting
Phase 3
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Cervical CancerVaginal CancerVulvar Cancer+12 more
Shanghai Bovax Biotechnology Co., Ltd.1,200 enrolled1 locationNCT04895020
Recruiting
Phase 3
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Vaginal CancerCIN1CIN2+4 more
Shanghai Bovax Biotechnology Co., Ltd.1,348 enrolled1 locationNCT05027776
Recruiting
Phase 3
TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Trans-Tasman Radiation Oncology Group200 enrolled17 locationsACTRN12613000279729
Completed
Phase 3
Human Papilloma Virus (HPV) Vaccination in Special Risk Groups
Special Risk Groups
1. Paediatric Rheumatalogical Disease
2. Inflammatory Bowel Disease
3. Acute Lymphoblastic Leukaemia
4. Solid Organ Transplant Recipients (kidney and liver)
5. Chronic Renal Disease
6. Bone Marrow Transsplant
The response to the HPV vaccine will be studied within these 6 special risk groups.
National Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation100 enrolled1 locationACTRN12609000571279